Vertex Pharmaceuticals has a rolling biologics license application with the FDA for povetacicept in IgA nephropathy. With new data from RAINIER, the biotech expects to complete its submission by the ...

I’ve had my Shark Rocket HV301 for seven years, and it has never let me down on hardwood floors, high-pile area rugs, or tile. Recently, I moved into a larger apartment with more furniture, more ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the company's innovation. The company recently has expanded into another area, too, and ...

Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big PBMs to cover the non-opioid pain drug. In what analysts called a “sticker ...

NEW YORK – A federal district court has ruled against Vertex Pharmaceuticals, thwarting its quest to provide fertility preservation treatment to patients receiving its gene-editing therapy through a ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial. The ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...